Key Highlights
- Dr. Karim Benhadji appointed as Chief Medical Officer, effective May 1, 2024.
- Robert Wasserman, M.D., retires and transitions to an advisory role.
- Ompenaclid (RGX-202) and abequolixron (RGX-104) highlighted as lead drug candidates.
- Inspirna’s RNA-DRIVEr™ platform emphasizes novel cancer target discovery.
Source: Business Wire
Notable Quotes
- “Bob was instrumental in transforming our pipeline and advancing important development candidates. We thank him for his invaluable contribution.” — Dr. Usman “Oz” Azam, M.D., Chief Executive Officer at Inspirna
- “Inspirna is differentiated by its proprietary target discovery platform RNA-DRIVEr™, and I am excited to work with this team to realize the full potential of this microRNA-based target discovery platform.” — Dr. Karim Benhadji, Chief Medical Officer at Inspirna
SoHC's Take
The appointment of Dr. Karim Benhadji as Chief Medical Officer marks a significant milestone for Inspirna. With Dr. Benhadji’s extensive experience in oncology drug development and his proven track record in bringing innovative treatments to market, Inspirna is well-positioned to advance its clinical programs. The leadership change comes at a pivotal time as Inspirna continues to develop its promising drug candidates, ompenaclid and abequolixron, which have the potential to address unmet needs in oncology. The company’s proprietary RNA-DRIVEr™ platform underscores its commitment to pioneering novel cancer therapies. This strategic leadership transition is likely to propel Inspirna towards achieving its clinical and commercial objectives, ultimately benefiting patients with difficult-to-treat cancers.
